PASADENA, Calif. --(BUSINESS WIRE)--Jan. 6, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the appointment of James Hassard to the newly-created position of chief commercial officer. Mr. Hassard will be responsible for driving commercial strategy and building the team and
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 20, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 16, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 6, 2019 , the Compensation Committee of the Board of Directors approved "inducement" grants to 21 new
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 16, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 13, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Marianne De Backer , Ph.D., as an independent director of the company, with a term beginning effective
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 11, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) for a Phase 1b adaptive dose-finding clinical study of ARO-HIF2, the
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 6, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on December 6, 2019 it closed the previously announced underwritten public offering of 4,600,000 shares of its common stock, which included shares issued upon the exercise in full
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 4, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $58.00 per share, before underwriting discounts.
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 2, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell 4,000,000 shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration statement.
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 26, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Jaffray 31st Annual Healthcare Conference – New York , December 3-5, 2019 December 3 , 11:00 a.m.